Reversing microtubule-directed chemotherapeutic drug resistance by co-delivering α2β1 inhibitor and paclitaxel with nanoparticles in ovarian cancer.
Previous reports indicated that integrins associated signals are tightly related to tumor progression. Here, we observed elevated expression of integrin α2β1 in tumor tissues from microtubule-directed chemotherapeutic drugs (MDCDs) resistant patients compared with those samples from chemo-sensitive patients. More importantly, we sorted the integrin α2β1+ tumor cells and found those cells reveal high MDCDs resistance whereas MDCDs shows effective cytotoxicity to those integrin α2β1- tumor cells in vitro and in vivo. Mechanistically, we demonstrated that integrin α2β1 could induce the MDCDs resistance through the activation of PI3K/AKT pathway. Applying MPEG-PLA to co-encapsulate integrin α2β1 inhibitor E7820 and MDCDs could effective reverse the MDCDs resistance, resulting in enhance anticancer effects while avoiding potential systemic toxicity in vitro and in vivo. In conclusion, the expression of integrin α2β1 contributes to the MDCDs resistance, while applying E7820 combination treatment by MPEG-PLA nanoparticles could reverse the resistance. This article is protected by copyright. All rights reserved.